However, our data show that while the single blockade of IL6R or CXCR2 could be efficacious in CML, this might not be the case for AML, in which the concomitant inhibition of their signals is critical to target AML ckit+ cells. This evidence concerns the gene IL6R and chronic myelogenous leukemia, BCR-ABL1 positive.